Advertisement
News
Advertisement

The Medicines Company Stock Trading Halted Today

Wed, 02/12/2014 - 8:01am

The Medicines Company announced today that NASDAQ has halted trading of the company's stock. The U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) is meeting today to discuss the new drug application (NDA) for cangrelor injection, for the proposed indication of reduction of thrombotic cardiovascular events including stent thrombosis (events related to blood clots in a stent, a device inserted to keep the artery open) in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).

The Medicines Company is also proposing that cangrelor be indicated to maintain P2Y12 inhibition in patients with acute coronary syndromes or patients with stents who are at increased risk for thrombotic events (such as stent thrombosis) when oral P2Y12 therapy is interrupted due to surgery. P2Y12 is a protein involved in blood clotting; inhibiting this protein is a key mechanism of action of cangrelor.

Topics

Advertisement
Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading